The Swiss Neurodevelopmental Outcome Registry for Children With CHD (SwissORCHID)
Introduction: Congenital heart disease (CHD) is the most frequent birth defect. As survival has significantly improved, attention has turned to neurodevelopmental outcomes of children undergoing heart surgery in early infancy. Since multiple risk factors contribute to neurodevelopmental alterations, a nationwide registry collecting data on medical characteristics, interventions, clinical course and neurodevelopment until school-age is needed to improve the quality of management, identify risk- and protective factors affecting neurodevelopment, and facilitate multicenter trials.
Methods and analysis: The Swiss Outcome Registry for CHIldren with severe congenital heart Disease (ORCHID) is a nationwide, prospective, population-based patient registry developed (1) to collect baseline characteristics and clinical data of CHD patients operated with bypass-surgery or hybrid procedures in the first 6 weeks of life in Switzerland, (2) to monitor long-term neurodevelopment, and (3) to relate clinical characteristics and neurodevelopment to identify risk and protective factors in these children. This registry started data collection relating to pregnancy, birth, preoperative course, catheter-based and surgical treatment, postoperative course and reinterventions in 2019. The primary outcome includes standardised neurodevelopmental assessments at 9 to 12 months, 18 to 24 months and 5.5 to 6 years. Investigators expect to include 80 to 100 children per year. Correlation and regression analyses will be used to investigate risk- and protective factors influencing neurodevelopment.
Ethics and dissemination of results: Swiss ORCHID received support by the Accentus Charitable Foundation, the Anna Mueller Grocholoski Foundation, the Swiss Society of Pediatric Cardiology, and the Corelina - Foundation and was approved by the cantonal ethics committees. Findings will be presented at national and international scientific meetings, and published in peer-reviewed journals. Results will also be shared with patient organizations, primary health care providers, and public health stakeholders to ensure a widespread dissemination of the results.
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Walter Knirsch, MD
- Phone Number: +41 44 266 7111
- Email: walter.knirsch@kispi.uzh.ch
Study Locations
-
-
-
Bern, Switzerland
- Recruiting
- University of Bern
-
Contact:
- Walter H Knirsch, MD
- Phone Number: +41442667617
- Email: walter.knirsch@kispi.uzh.ch
-
Contact:
- Damian Hutter, MD
- Email: damian.hutter@insel.ch
-
Lausanne, Switzerland
- Recruiting
- University of Lausanne
-
Contact:
- Nicole Sekarski, MD
- Email: nicole.sekarski@chuv.ch
-
Contact:
- Walter Knirsch, MD
- Email: walter.knirsch@kispi.uzh.ch
-
Zurich, Switzerland, 8032
- Recruiting
- University Children's Hospital
-
Contact:
- Walter H Knirsch, MD
- Phone Number: +41442667617
- Email: walter.knirsch@kispi.uzh.ch
-
Contact:
- H
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Neonates (including preterm born children) with severe CHD
- Requiring an invasive cardiac intervention (including heart-lung-machine) within the first 6 weeks of life.
Exclusion Criteria:
- Neonates (including preterm born children) with simple CHD
- Requiring simple cardiac surgery or catheter intervention such as closure of patent arterial duct or simple repair of aortic coarctation without heart-lung-machine and low impact on neurodevelopmental outcome.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bayley scales of infant and toddler development III at one year of age
Time Frame: One year of age
|
Neurodevelopmental outcome measurement at one year of age (normal value 100, higher values mean better outcome)
|
One year of age
|
|
Bayley scales of infant and toddler development III at two years of age
Time Frame: Two years of age
|
Neurodevelopmental outcome measurement at two years of age (normal value 100, higher values mean better outcome)
|
Two years of age
|
|
Bayley scales of infant and toddler development III at five years of age
Time Frame: Five years of age
|
Neurodevelopmental outcome measurement at five years of age (normal value 100, higher values mean better outcome)
|
Five years of age
|
Collaborators and Investigators
Investigators
- Principal Investigator: Walter Knirsch, MD, University Children's Hospital, Zurich
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Knirsch 02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.